News | January 28, 2025
Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Subscribe To Our Newsletter & Stay Updated
